U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C16H22ClNO4
Molecular Weight 327.803
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CLOFIBRIDE

SMILES

CN(C)C(=O)CCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1

InChI

InChIKey=CXQGFLBVUNUQIA-UHFFFAOYSA-N
InChI=1S/C16H22ClNO4/c1-16(2,22-13-9-7-12(17)8-10-13)15(20)21-11-5-6-14(19)18(3)4/h7-10H,5-6,11H2,1-4H3

HIDE SMILES / InChI

Description

Clofibride is a hypolipaemic drug of p-chlorophenoxyisobutyric type. Clofibride hypolipaemic effects could be due, partially, to a reduction of hormono-dependent lipolysis. Clofibride decreased blood cholesterol and total lipids, increased liver weight and liver catalase content, and decreased biliary excretion of cholesterol in normolipidemic rats after a 7 day treatment.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
Healthy volunteers received therapeutic doses of clofibrate as 2x500 mg capsules, clofibride as 2x450 mg capsules, twice daily for ten days.
Route of Administration: Oral
In Vitro Use Guide
One dose of clofibride (Cf) is administered, after sacrifice of normal fasting rat, in vitro: 2 mg/100 mg adipocytes in 2 ml medium.